14 results about "Cell adhesion molecule" patented technology

The invention provides an application of a carcino-embryonic antigen related cell adhesion molecule 5 (CEACAM5) in treatment of pancreatic cancer. Research finds that a novel stem cell-like cluster cell subtype (hereinafter referred to as' stem cell-like TCs') is found, and the subtype is significantly related to poor prognosis of pancreatic ductal adenocarcinoma patients. Therefore, the invention provides a novel pancreatic ductal adenocarcinoma treatment medicine, namely the carcino-embryonic antigen related cell adhesion molecule 5, which has very positive significance on the treatment of the pancreatic ductal adenocarcinoma.

A modified cell is provided that expresses (a) a chimeric antigen receptor targeting GPC3 and / or CD19, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule), and a second antigen binding protein, variant or binding fragment thereof, which binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof, which binds to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of generating / generating cells as disclosed herein and methods of treating with cells as disclosed herein.

Peptides, proteins, antibodies, antibody fragments, or antigen-binding fragments thereof, against cell adhesion molecules for use as immunotherapeutics.

The invention belongs to the technical field of medicines, and discloses application of berberine serving as an active ingredient of rhizoma coptidis to preparation of a medicine for preventing and / or treating vascular injury. According to the application disclosed by the invention, an action target of berberine serving as a core component of coptis chinensis is predicted through network pharmacology, and then a tumor necrosis factor-alpha stimulated human umbilical vein endothelial cell (HUVEC) model is used for verification; it is proved that berberine down-regulates the expression of downstream key inflammatory factors (IL-6 and IL-8), monocyte chemotactic protein-1 (MCP-1), cell adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). Based on this, the invention provides a candidate drug with novel mechanism and multi-target effect for prevention and treatment of atherosclerosis, and has important development value and application prospect.

The application discloses application of ferritin-carrying neuron-derived extracellular vesicles in auxiliary diagnosis of Parkinson's disease and belongs to the field of biomedical technology. The application realizes effective identification of specific ferritin-carrying neuron-derived extracellular vesicles in a flow cytometer by fluorescence labeling of L1 cell adhesion molecule antibodies and ferritin heavy chain antibodies, and can accurately distinguish PD patients, MSA patients and healthy people by analyzing the concentration of the ferritin-carrying neuron-derived extracellular vesicles in blood plasma, thereby providing an efficient PD diagnosis biomarker and greatly improving the ability of early diagnosis of PD and identification of MSA and PD, and effectively solving the problems of complexity and low sensitivity faced by traditional diagnosis methods.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.30

An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying the expression of the cell adhesion molecule in the population of isolated mammalian stem cells to decrease or knockout expression of the cell adhesion molecule and provide the population of hypoimmune mammalian cells. The population of isolated mammalian stem cells can be pluripotent stem cells, or embryonic stem cells, and can be human or non-human stem cells.

This invention discloses a mitochondrial uncoupling agent prodrug with endothelial cell targeting, its preparation method, and its application, relating to the field of biomedical technology. The prodrug is covalently coupled to a vascular cell adhesion molecule-1 targeting polypeptide (amino acid sequence FAKELMEEFEKW), a reactive oxygen species-sensitive thioacetate linker, and the mitochondrial uncoupling agent OPC-163493. This invention utilizes the active enrichment effect of the targeting polypeptide on inflamed pulmonary vascular endothelial cells, overcoming the off-target defects of non-specific distribution in existing small molecule drugs; simultaneously, it utilizes the specific cleavage characteristics of the thioacetate linker in a microenvironment rich in reactive oxygen species to achieve precise in-situ drug release. This prodrug can effectively reduce mitochondrial reactive oxygen species generation, inhibit endothelial cell apoptosis, significantly reduce pulmonary vascular permeability, and alleviate pulmonary edema, possessing significant clinical application value in the preparation of drugs for treating acute lung injury or acute respiratory distress syndrome.

The present disclosure is directed to methods for preventing or treating helminth (e.g., filarial) diseases in animals. The methods are accomplished by administering to the animal a therapeutically effective amount of an inhibitor of UDP-glucoronosyl transferase (UGT) or immunoglobulin I-set domain containing protein (Igl-DCP, also known as BMA-Lad-2). The inhibitors include those known to inhibit glucuronyltransferase enzyme activity as well as cell adhesion molecule inhibitors and antibodies specific for Igl-DCP and / or UGT.

A pharmaceutical composition comprising a compound that targets and / or binds to a binding pocket at interface between the D1 and D2 domains of an intracellular portion or fragment of the receptor protein tyrosine phosphatase (RPTP) IIb cell adhesion molecules (e.g., PTPμ) and that is capable of inhibiting RPTP mediated adhesion of cells and / or cancer cell growth and / or sphere formation.

Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.

The application discloses a kind of miRNA-21-5p-rich exosomes and its preparation method and application.The preparation method includes the following steps: culturing mesenchymal stem cells in culture medium containing promoting agent, collecting supernatant, and obtaining miRNA-21-5p-rich exosomes by separation;The promoting agent includes at least one of vascular cell adhesion molecule-1, tumor necrosis factor alpha and interleukin-6.The method can obtain miRNA-21-5p-rich exosomes;The exosome has a therapeutic effect on diabetic foot ulcers, and the therapeutic effect is significantly better than that of exosomes prepared by traditional methods.

The present invention relates to inhibitors of the interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.